Pulsar Helium (LON: PLSR) executive chair Neil Herbert exercised nearly 1.6 million options at C$0.45 each, raising C$719,000 for the company. The share price increased 17.5% to 121p.
Abingdon Health (LON: ABDX) has won a series of contracts worth £4.8m with a US client. This covers the development of multiplex quantitative lateral flow assay systems for human testing which will be delivered over 27 months. This supports the decision to expand capacity in the US. There could be a subsequent manufacturing contract. The company is set to move to around breakeven in 2026-27. The share price gained 10.3% to 8p.
Monoclonal antibodies developer Bioventix (LON: BVXP) reported interim revenues 9% lower at £6.2m. China was a tough market and some products are maturing. Pre-tax profit was slightly lower at £4.9m. Cash was £5.1m at the end of 2025. The customer base is being broadened and there is longer-term potential for royalties from the company’s antibodies that are included in products. Full year pre-tax profit is set to fall from £10.2m to £9.6m. The full year dividend is set to be unchanged at 150p/share even though it is not going to be covered by earnings. The share price recovered 9.09% to £15.
Security printing and authentication services provider Spectra Systems (LON: SPSY) more than doubled pre-tax profit to $25.2m on revenues 31% ahead at $64.3m in 2025. This was boosted by a major contract. The dividend is 17% higher at 13.6p/share. Net cash is $11.1m. The closure of the business in France has been delayed. Zeus has upgraded its 2026 pre-tax profit forecast by 12.5% to $11.1m. The share price rose 8.73% to 137p.
FALLERS
In-game advertising technology developer Mirriad Advertising (LON: MIRI) says that the expected upturn in February and March did not happen because of the Middle East conflict. It did sign a services agreement with a UK media conglomerate. There is £675,000 in the bank, but more cash will be required before the 2025 accounts are published. The share price dived 63.6% to 0.002p.
Pri0r1ty Intelligence (LON: PR1) says auditors still have not completed the audit for the year to September 2025 and trading in the shares will be suspended on 1 April. The AI business undertook two acquisitions, including a reversal, last year which complicates the accounts. There is also an impairment review on intangible assets. The share price slipped by one-fifth to 1.6p.
Wound healing technology developer AOTI Inc (LON: AOTI) says 2025 revenues were $66.5m, up 15% on 2024. Underlying pre-tax profit was $3.1m, compared with a loss last year. Net debt reached $6.5m. There is a $1.7m provision on money owed by Arizona. Revenues could still rise this year even though AOTI is pulling out of Arizona due to difficulty in getting paid, but profit could decline to $1.2m before starting to grow again. Outstanding debt from Arizona may eventually be reclaimed. A CMS local coverage determination is still expected in the near-term and that will provide some positivity. The share price declined 13.65 to 28.5p.
Graphene technology developer Directa Plus (LON: DCTA) is in discussions with an institution that could provide funding of up to £2.5m. This would require shareholder approval. Talks with Nant Capital ended without agreement on a non-dilutive loan. Directa Plus has enough cash until May but needs more funds to continue trading after that. The sale of a property could raise €500,000 and the Sectar subsidiary could also be sold. The share price fell 11.8% to 7.5p.